United Therapeutics Corporation (UTHR) Receives Average Recommendation of “Hold” from Analysts

United Therapeutics Corporation (NASDAQ:UTHR) has been assigned an average recommendation of “Hold” from the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $131.78.

A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of United Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. TheStreet downgraded shares of United Therapeutics from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Cowen reissued a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a research note on Friday, October 27th. HC Wainwright reissued a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a research note on Thursday, October 26th. Finally, ValuEngine downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 8th.

In related news, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the completion of the sale, the director now directly owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,232 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $133.32, for a total transaction of $164,250.24. Following the sale, the chief executive officer now directly owns 2,301 shares of the company’s stock, valued at $306,769.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,659 shares of company stock valued at $2,759,490. Company insiders own 7.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in UTHR. Wells Fargo & Company MN grew its holdings in United Therapeutics by 144.0% during the 2nd quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock worth $94,785,000 after acquiring an additional 431,210 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in United Therapeutics by 308.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock worth $64,930,000 after acquiring an additional 378,002 shares in the last quarter. Renaissance Technologies LLC grew its holdings in United Therapeutics by 65.5% during the 2nd quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock worth $108,662,000 after acquiring an additional 331,400 shares in the last quarter. Schroder Investment Management Group grew its holdings in United Therapeutics by 42.8% during the 2nd quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock worth $143,359,000 after acquiring an additional 327,360 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in United Therapeutics by 58.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 726,760 shares of the biotechnology company’s stock worth $94,286,000 after acquiring an additional 266,790 shares in the last quarter. 99.83% of the stock is owned by institutional investors.

United Therapeutics (NASDAQ UTHR) traded up $0.87 during trading hours on Thursday, reaching $129.99. 550,347 shares of the company’s stock were exchanged, compared to its average volume of 558,891. The stock has a market capitalization of $5,560.00, a P/E ratio of 10.98 and a beta of 1.38. United Therapeutics has a 12 month low of $112.01 and a 12 month high of $169.89.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. The company had revenue of $445.50 million for the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics’s revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the firm posted $4.23 earnings per share. analysts forecast that United Therapeutics will post 12.29 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/30/united-therapeutics-corporation-uthr-receives-average-recommendation-of-hold-from-analysts.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply